Jones Financial Companies Lllp Grows Stock Holdings in Solventum Co. (NYSE:SOLV)

Jones Financial Companies Lllp lifted its position in Solventum Co. (NYSE:SOLV) by 14.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,366 shares of the company’s stock after purchasing an additional 418 shares during the period. Jones Financial Companies Lllp’s holdings in Solventum were worth $222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently added to or reduced their stakes in the stock. Modus Advisors LLC purchased a new position in Solventum during the fourth quarter worth about $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum during the fourth quarter worth about $26,000. Crews Bank & Trust acquired a new stake in shares of Solventum during the fourth quarter worth about $32,000. True Wealth Design LLC raised its holdings in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in Solventum in the third quarter valued at approximately $35,000.

Solventum Price Performance

Solventum stock opened at $72.44 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The firm has a market cap of $12.53 billion and a P/E ratio of 26.34. The business’s fifty day moving average is $74.37 and its two-hundred day moving average is $70.97.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Morgan Stanley boosted their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Finally, Bank of America boosted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.